NCT02113813 2024-11-14A Dose Escalation Study of ASP8273 in Subjects With Non-Small-Cell Lung Cancer (NSCLC) Who Have Epidermal Growth Factor Receptor (EGFR) MutationsAstellas Pharma IncPhase 1 Completed133 enrolled